Drugs‎ > ‎

Aripiprazole

Class
  • Benzisoxazole derivative atypical antipsychotic
Indications
Administration/Absorption
  • Oral
  • IM
Dosage

Distribution
  • VOD 4.9 L/kg
Mechanism
  • Dopamine normaliser
    • Stimulates if levels low
    • Inhibits if levels high
  • Selective monoaminergic antagonist with high affinity for:
    • Serotonin Type 2 (5HT2)
    • Dopamine Type 2 (D2)
    • 1 and 2 adrenergic
    • H1 histaminergic
  • Aripiprazole's antipsychotic activity is likely due to a combination of antagonism at:
    • D2 receptors in the mesolimbic pathway
    • 5HT2A receptors in the frontal cortex
  • Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia
Excretion
  • Hepatic metabolism
  • Urine / faeces
  • Halflife 75-146 hours
Side effects
  • akathisia
  • headache
  • agitation
  • anxiety
  • unusual tiredness or weakness
  • nausea and vomiting
  • an uncomfortable feeling in the stomach
  • constipation
  • increased production of saliva
  • light-headedness
  • insomnia
  • sleepiness
  • shaking
  • blurred vision
  • sexual dysfunction
Interactions

Contraindications

Comments